BD Medical, a part of leading medical technology firm Becton, Dickinson and Company (BDX - Analyst Report) , recently revealed that the BD UltraSafe PLUS Passive Needle Guard had received 510(k) clearance. Subsequently, this offering has been commercialized as BD Medical’s latest passive needle guard product. It is intended to satisfy complicated biotech drug needs, which includes greater viscosity.
In addition to providing needlestick safety, the BD UltraSafe PLUS Passive Needle Guard includes ergonomic aspects. Its modern design includes sophisticated features such as a strong plunger rod to facilitate injection of viscous medicines.
The BD UltraSafe PLUS Passive Needle Guard is in congruence with ISO marked prefilled syringes. This offering was created by Safety Syringes, Inc., an anti-needlestick device firm which was taken over by Becton Dickinson in Dec 2012.
We remain cautious about Becton Dickinson due to the lack of major short-term catalysts. The rising demand for safety-needle products (with higher price points and margins) was the primary driver of the company’s past growth. This is not expected to continue, given that the U.S. market is already largely penetrated.
On the positive side, Becton Dickinson’s preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.
Becton Dickinson faces a wide range of competitors, including Baxter International (BAX - Analyst Report) in certain niches, in each of its three business segments. The stock retains a Zacks Rank #3 (Hold).
Henry Schein, Inc. (HSIC - Analyst Report) and The Cooper Companies Inc. (COO - Analyst Report) currently each retain Zacks Rank #2 (Buy) and are expected to do well.